Recursion Pharmaceuticals Inc is trading 10.8% up at $3.85 on unusually strong early-session buying interest, rebounding from a period of recent weakness.
- No fresh company-specific headlines, earnings, FDA decisions, or major analyst calls have been published as of June 4, 2026.
- The upward move appears to be driven by short-term trading, bargain hunting, and general volatility across AI and biotechnology stocks rather than a new fundamental catalyst.